Key result
Bicuspid aortic valve specimens showed less inflammation than tricuspid valves, and molecular markers like c-Kit identified a non-dilated subgroup susceptible to aortopathy.
Why the study?
Can molecular biological markers in the aortic wall identify bicuspid aortic valve patients susceptible to future aortopathy?
Observational (n=59)
Can molecular biological markers in the aortic wall identify bicuspid aortic valve patients susceptible to future aortopathy?
Molecular tissue markers, particularly c-Kit and its downstream targets, can identify a subgroup of non-dilated bicuspid aortic valve patients who may be at high risk for future aortic dilatation.
Answers are grounded in this paper and cite their sources.
May aid aortopathy risk stratification in non-dilated BAV via c-Kit; hypothesis-generating and requires prospective validation.
OBJECTIVES: The clinical course of many patients with a bicuspid aortic valve (BAV) is complicated by ascending aortic dilatation. Currently, the indication for aortic surgery is solely based on the aortic diameter and subsequently only a small proportion of BAV patients undergoing valve surgery require concomitant ascending aortic replacement based on these recommendations. Unfortunately, a substantial number of BAV patients still develop aortic dilatation in the future and would potentially benefit from a more aggressive approach towards ascending aortic replacement. We, therefore, designed this study to identify molecular biological markers in the aortic wall predictive of aortopathy in BAV. METHODS: Ascending aortic wall specimen of BAV (n = 36) and tricuspid aortic valve (TAV) (n = 23), both without and with (>44 mm) dilatation were investigated histologically and immunohistochemically for the expression of markers for vascular remodelling [transforming growth factor (TGF)-β, phosphorylated Smad2, matrix metalloproteinase 9 (MMP9)], cellular differentiation [c-Kit, phosphorylated-c-Kit, hypoxia-inducable factor-1 alpha (HIF1α)] and haemodynamic influences on the aortic wall [endothelial nitric oxide (eNOS)]. RESULTS: All BAV patients showed significantly less inflammation (P < 0.001) and an altered intima/media ratio when compared with TAV patients. The expression of markers of a signalling pathway characteristic for cellular dedifferentiation, as exemplified by the marked expression of c-Kit, phosphorylated c-Kit and HIF1α; in the dilated BAV group was however completely comparable with only a subgroup of the non-dilated BAV (BAb), whereas the remainder of the non-dilated BAV group (BAa) was significantly distinct. This difference between the dilated BAV and BAa was further confirmed in the expression of TGF-β, phosphorylated Smad2, MMP9 and eNOS. Besides the expression pattern, similarity in the dilated BAV and BAb was also noted clinically in the most common variant of commissure position and conjoined raphe of the BAV. Based on these observations, we consider the BAb group a likely candidate for future dilatation as opposed to the BAa group. CONCLUSIONS: Using a panel of molecular tissue markers, the non-dilated BAV patients can be divided into groups susceptible and non-susceptible to aortopathy.
No takes yet. Share an insight, caveat, or question.
Grewal et al. (2014) conducted an observational in Bicuspid aortic valve and aortopathy (n=59). Bicuspid aortic valve (BAV) vs. Tricuspid aortic valve (TAV) was evaluated on Inflammation and expression of molecular markers (c-Kit, TGF-β, etc.) (p=<0.001). Bicuspid aortic valve specimens showed less inflammation than tricuspid valves, and molecular markers like c-Kit identified a non-dilated subgroup susceptible to aortopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: